Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Phase 1 save search
Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
Published: 2023-03-28 (Crawled : 12:00) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 1.97%
H: 0.0%
C: -2.68%
trial therapeutics plus phase 1
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735
Published: 2023-03-28 (Crawled : 11:00) - prnewswire.com
VKTX | $65.03 0.15% 0.15% 2.6M
|
Health Technology
|
| O: 34.98%
H: 25.83%
C: 25.43%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -0.07%
H: 5.37%
C: 4.8%
vk2735 agonist trial therapeutics results endocrine disorders obesity phase 1
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
Published: 2023-03-23 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.52%
H: 0.46%
C: -0.9%
BBIO | $25.02 -1.73% -1.76% 1.5M
|
Health Technology
|
| O: 0.62%
H: 5.65%
C: 5.11%
bbp-398 opdivo lung pharma cancer trial phase 1
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
Published: 2023-03-22 (Crawled : 13:00) - biospace.com/
HUGE | News | $0.4634 -5.24% -5.52% 280K
|
Process Industries
|
| O: 0.65%
H: 3.21%
C: 0.0%
pharma candidate approval treatment trial potential phase 1 major depressive disorder
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal MetastasesFirst data readout of Phase 1/Part A trial expected second half of 2023
Published: 2023-03-22 (Crawled : 12:00) - biospace.com/
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 3.12%
H: 1.39%
C: 0.0%
expected readout trial therapeutics plus phase 1
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases
Published: 2023-03-22 (Crawled : 11:00) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 3.12%
H: 1.39%
C: 0.0%
trial therapeutics plus phase 1
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
Published: 2023-03-20 (Crawled : 12:20) - globenewswire.com
VAXX | $0.13 -35.0% -53.85% 4.6M
|
|
| O: -2.88%
H: 2.72%
C: 0.99%
vxx-401 vaccine trial hypercholesterolemia phase 1
Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial
Published: 2023-03-16 (Crawled : 13:00) - globenewswire.com
DERM | $3.425 -3.25% -3.36% 60K
|
|
| O: -4.96%
H: 15.3%
C: 10.07%
FBIO | $1.785 -1.38% -1.4% 120K
|
Health Technology
|
| O: 2.54%
H: 0.0%
C: 0.0%
dfd-29 corporation treatment impact medical trial phase 1
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
PYXS | $4.445 -1.22% -1.24% 230K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 7.46%
C: 7.46%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.55%
H: 1.07%
C: 0.77%
pyx-201 tumors trial phase 1
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
ABUS | $2.74 -0.36% -0.36% 340K
|
Health Technology
|
| O: -0.33%
H: 0.12%
C: -2.65%
ab-161 trial phase 1
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
Published: 2023-03-14 (Crawled : 22:00) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: -44.77%
H: 1.05%
C: -9.73%
trials phase 1
Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
Published: 2023-03-13 (Crawled : 12:00) - biospace.com/
MRSN | $2.89 -9.97% -11.07% 3.2M
|
Health Technology
|
| O: -12.12%
H: 13.3%
C: 12.81%
xmt-2056 trial therapeutics clinical hold phase 1
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
Published: 2023-03-08 (Crawled : 19:00) - biospace.com/
VTGN | $4.75 -1.66% -1.68% 150K
|
Health Technology
|
| O: 2.12%
H: 2.52%
C: -5.6%
ph10 spray trial phase 1 major depressive disorder
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
Published: 2023-03-08 (Crawled : 13:00) - biospace.com/
SEOVF | $0.3252 15.67% 20K
|
Health Technology
|
| O: 1.27%
H: 4.0%
C: -2.5%
treatment trial diabetes phase 1
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
Published: 2023-03-07 (Crawled : 21:00) - globenewswire.com
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
BICX | $0.75 201.91% 4.2K
|
Health Care and Social Assistan...
| Email alert
Add to watchlist
meeting trial positive results phase 1
Skye Bioscience Doses Third Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
Published: 2023-03-07 (Crawled : 15:00) - biospace.com/
SKYE | $12.845 -8.45% -9.23% 110K
|
Transportation and Warehousing
|
| O: -9.67%
H: 10.33%
C: 7.01%
sbi-100 trial bioscience ophthalmic emulsion phase 1
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
DYAI 4 | $1.52 2.01% 1.97% 3.4K
|
Health Technology
|
| O: -0.71%
H: 21.43%
C: 20.71%
dyai-100 covid-19 candidate protein vaccine trial update phase 1
Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
CELZ | $4.8201 0.21% 8.8K
|
|
| O: 1.56%
H: 0.0%
C: -6.18%
SYNH | $42.98 0.0% 7.4M
|
Health Services
|
| O: 0.03%
H: 0.45%
C: -1.01%
celz-201 medical technology trial diabetes international phase 1
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma
Published: 2023-03-03 (Crawled : 14:00) - biospace.com/
APM | $5.69 3.45% 3.34% 17K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.23%
fda drug meeting repurposed group phase 1
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
CYBN | $0.355 -1.44% 3.5M
|
n/a
|
| O: 2.11%
H: 4.93%
C: -9.06%
cyb003 program cyb004 trial positive update psilocybin phase 1
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.